Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

NPCE

NeuroPace Inc

Dec 26 • 04:00PM ET

11.35

Dollar change +0.21
Percentage change 1.89	%

Healthcare • Medical Devices • USA • NASD

Peers: MDT BSX SYK PODD LIVN NVRO EW ZBH ISRG STAA

| Held by: VTI IWM VXF IWO VTWO IWC VTWG RSSL UWM URTY

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.99	Insider Own	52.86%	Shs Outstand	29.78M	Perf Week	6.67%
Market Cap	334.28M	Forward P/E	-	EPS next Y	-0.88	Insider Trans	-2.06%	Shs Float	14.07M	Perf Month	6.47%
Income	-28.09M	PEG	-	EPS next Q	-0.25	Inst Own	38.16%	Short Float	1.79%	Perf Quarter	68.90%
Sales	76.45M	P/S	4.37	EPS this Y	20.78%	Inst Trans	2.32%	Short Ratio	3.09	Perf Half Y	62.14%
Book/sh	0.33	P/B	34.41	EPS next Y	12.60%	ROA	-28.72%	Short Interest	0.25M	Perf Year	14.65%
Cash/sh	1.93	P/C	5.88	EPS next 5Y	-	ROE	-214.55%	52W Range	5.45 - 18.15	Perf YTD	10.09%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-0.33%	ROI	-34.46%	52W High	-37.47%	Beta	2.06
Dividend TTM	-	Quick Ratio	4.77	Sales past 5Y	16.39%	Gross Margin	73.83%	52W Low	108.26%	ATR (14)	0.90
Dividend Ex-Date	-	Current Ratio	5.59	EPS Y/Y TTM	33.80%	Oper. Margin	-30.17%	RSI (14)	58.83	Volatility	9.96% 9.10%
Employees	171	Debt/Eq	7.48	Sales Y/Y TTM	27.00%	Profit Margin	-36.74%	Recom	1.00	Target Price	16.17
Option/Short	Yes / Yes	LT Debt/Eq	7.30	EPS Q/Q	33.60%	Payout	-	Rel Volume	0.70	Prev Close	11.14
Sales Surprise	10.42%	EPS Surprise	29.26%	Sales Q/Q	28.20%	Earnings	Nov 12 AMC	Avg Volume	81.36K	Price	11.35
SMA20	1.55%	SMA50	25.78%	SMA200	26.94%	Trades		Volume	56,613	Change	1.89%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-14-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$16 → $20
Jan-30-24	Initiated	Leerink Partners	Outperform	$22
Nov-10-23	Initiated	Cantor Fitzgerald	Overweight	$11
Aug-24-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$5 → $6
Feb-22-23	Initiated	Lake Street	Buy	$10
Apr-06-22	Initiated	Wolfe Research	Outperform	$13
Jan-19-22	Downgrade	Wells Fargo	Overweight → Equal Weight	$11
Jan-07-22	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$17 → $12
Nov-11-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-18-21	Initiated	Robert W. Baird	Outperform	$26
May-17-21	Initiated	Wells Fargo	Overweight	$25
May-17-21	Initiated	SVB Leerink	Outperform	$25
May-17-21	Initiated	Morgan Stanley	Overweight	$26
May-17-21	Initiated	JP Morgan	Overweight	$27

Show Previous Ratings

Dec-25-24 12:00PM	NeuroPace (NPCE) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Dec-18-24 04:05PM	NeuroPace to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -7.64%
Dec-12-24 04:05PM	NeuroPace to Host Investor Day on January 28th in New York City (GlobeNewswire)
Dec-06-24 09:55AM	Wall Street Analysts Think NeuroPace (NPCE) Could Surge 31.47%: Read This Before Placing a Bet (Zacks)
Dec-04-24 04:05PM	NeuroPace to Showcase the RNS System at the 2024 American Epilepsy Society (AES) Annual Meeting (GlobeNewswire) -6.20%
04:05PM	Loading…
Dec-03-24 04:05PM	NeuroPace Completes Enrollment in Feasibility Study of RNS System for Lennox-Gastaut Syndrome (GlobeNewswire) +5.67%
Nov-18-24 12:00PM	What Makes NeuroPace (NPCE) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 54.34%: Here's is How to Trade (Zacks)
Nov-13-24 02:18AM	NeuroPace Inc (NPCE) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Growth ... (GuruFocus.com) +28.15%
Nov-12-24 06:00PM	NeuroPace, Inc. (NPCE) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:54PM	NeuroPace Inc.: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	NeuroPace Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance (GlobeNewswire)
Nov-11-24 07:18AM	Earnings To Watch: NeuroPace Inc (NPCE) Reports Q3 2024 Result (GuruFocus.com)
Nov-04-24 04:05PM	NeuroPace Announces FDA Submission of Three-Year Data from Post-Approval Study of the RNS System in Focal Epilepsy (GlobeNewswire) +9.73%
Oct-28-24 09:08PM	KCK LTD.'s Strategic Reduction in NeuroPace Inc Shares (GuruFocus.com)
08:04AM	Loading…
08:04AM	Strength Seen in NeuroPace (NPCE): Can Its 5.1% Jump Turn into More Strength? (Zacks)
Oct-24-24 09:08PM	KCK LTD. Adjusts Stake in NeuroPace Inc (GuruFocus.com) +5.13%
Oct-22-24 04:05PM	NeuroPace to Report Third Quarter 2024 Financial Results on November 12, 2024 (GlobeNewswire)
03:01PM	KCK LTD.'s Strategic Reduction in NeuroPace Inc Shares (GuruFocus.com)
Oct-18-24 03:01PM	KCK LTD. Reduces Stake in NeuroPace Inc (GuruFocus.com)
Oct-16-24 04:05PM	NeuroPace Continues to Strengthen Management Team (GlobeNewswire)
Oct-03-24 07:04PM	KCK LTD. Reduces Stake in NeuroPace Inc (GuruFocus.com)
Sep-04-24 04:05PM	NeuroPace Strengthens Management Team with Two Key Appointments (GlobeNewswire)
Aug-27-24 04:05PM	NeuroPace Announces Participation at Two Upcoming Healthcare Investor Conferences (GlobeNewswire)
Aug-22-24 04:05PM	NeuroPace to Participate in Upcoming Healthcare Conferences in September (GlobeNewswire) -5.65% +12.98%
Aug-20-24 07:37AM	NeuroPace (NPCE) Q2 Earnings Beat, '24 Sales View Up (Zacks)
Aug-13-24 04:05PM	NeuroPace Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance (GlobeNewswire) +5.51% -7.01%
Jul-23-24 04:05PM	NeuroPace to Report Second Quarter 2024 Financial Results on August 13, 2024 (GlobeNewswire) +10.59%
May-14-24 04:05PM	NeuroPace to Participate in Two Healthcare Conferences in May (GlobeNewswire) +6.11%
May-13-24 10:46AM	NeuroPace, Inc. (NASDAQ:NPCE) Q1 2024 Earnings Call Transcript (Insider Monkey)
06:53AM	Loading…
06:53AM	Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating (MT Newswires)
May-10-24 03:38PM	NeuroPace Inc (NPCE) Q1 2024 Earnings: Revenue Surpasses Estimates Amidst Ongoing Challenges (GuruFocus.com) +6.65%
May-09-24 03:47AM	NeuroPace Inc (NPCE) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and Improved ... (GuruFocus.com) -36.75%
May-08-24 04:05PM	NeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -5.26%
Apr-17-24 04:05PM	NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024 (GlobeNewswire)
Apr-04-24 12:20PM	Time to Hit Buy, Says Wells Fargo About These 2 Stocks (TipRanks)
Mar-27-24 04:05PM	NeuroPace to Present at the Needham 23rd Annual Healthcare Conference (GlobeNewswire)
Mar-07-24 11:44AM	NeuroPace, Inc. (NASDAQ:NPCE) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-06-24 06:28AM	Q4 2023 Neuropace Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-05-24 09:52PM	NPCE Stock Earnings: NeuroPace Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
04:05PM	NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million (GlobeNewswire)
02:00PM	Financial Freedom Fighters: 3 Stocks to Liberate Your Portfolio (InvestorPlace)
Feb-23-24 05:15AM	20 Most Valuable Digital Health Companies In The US (Insider Monkey) +11.17%
Feb-15-24 04:05PM	NeuroPace to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024 (GlobeNewswire)
Feb-07-24 03:13AM	NeuroPace Inc Chief Medical Officer Martha Morrell Sells 17,589 Shares (GuruFocus.com) +5.80%
Feb-01-24 11:02PM	NeuroPace Inc Chief Medical Officer Martha Morrell Sells 13,848 Shares (GuruFocus.com)
Jan-08-24 07:03AM	NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023 and Provides Business Updates (GlobeNewswire) +12.89%
Dec-29-23 09:01PM	NeuroPace Inc Chief Medical Officer Martha Morrell Sells 13,402 Shares (GuruFocus.com) -5.14%
Dec-21-23 07:07AM	NeuroPace Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study (GlobeNewswire)
Dec-19-23 04:30PM	NeuroPace to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.68% -6.36%
Dec-04-23 05:07PM	NeuroPace to Leverage the Power of its RNS System's Novel Data Collection, Brain Monitoring and Analysis Capabilities in Groundbreaking Collaboration (GlobeNewswire) -8.65%
Dec-01-23 08:00AM	NeuroPace and the RNS System Showcased at the 77th American Epilepsy Society (AES) Annual Meeting (GlobeNewswire)
Nov-21-23 08:00AM	NeuroPace to Present at the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Nov-07-23 09:45AM	NeuroPace, Inc. (NASDAQ:NPCE) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-06-23 04:33PM	NeuroPace Inc (NPCE) Reports 47% YoY Revenue Growth in Q3 2023, Raises Full Year Revenue Guidance (GuruFocus.com)
04:03PM	NeuroPace Reports Third Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance (GlobeNewswire)
Oct-26-23 10:33AM	12 Best Performing NASDAQ Stocks in 2023 (Insider Monkey)
Oct-17-23 04:05PM	NeuroPace Announces RNS System Enhancements Designed to Streamline Care (GlobeNewswire)
Oct-16-23 05:01PM	NeuroPace to Report Third Quarter 2023 Financial Results on November 6, 2023 (GlobeNewswire)
Oct-05-23 01:02AM	OrbiMed Advisors LLC Reduces Stake in NeuroPace Inc (GuruFocus.com)
Sep-29-23 03:16PM	20 Countries With Highest Rate of Epilepsy (Insider Monkey)
Sep-20-23 04:05PM	NeuroPace to Participate in 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire) -5.39%
Aug-24-23 04:05PM	NeuroPace to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.95% +16.28%
Aug-13-23 08:03AM	Rainbows and Unicorns: NeuroPace, Inc. (NASDAQ:NPCE) Analysts Just Became A Lot More Optimistic (Simply Wall St.)
Aug-08-23 04:03PM	NeuroPace Reports Second Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance (GlobeNewswire) +9.76%
Jul-19-23 04:03PM	NeuroPace Announces Inducement Grants Under Listing Rule 5635(c)(4) of The Nasdaq Stock Market (GlobeNewswire)
Jul-18-23 04:05PM	NeuroPace to Report Second Quarter 2023 Financial Results on August 8, 2023 (GlobeNewswire)
Jun-28-23 04:03PM	NeuroPace Announces CEO Transition (GlobeNewswire)
May-24-23 04:05PM	NeuroPace Announces Addition of Kelley Nicholas as Vice President, Sales (GlobeNewswire)
May-05-23 10:13AM	Q1 2023 Neuropace Inc Earnings Call (Thomson Reuters StreetEvents)
May-04-23 04:05PM	NeuroPace Reports First Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance (GlobeNewswire)
Apr-17-23 04:05PM	NeuroPace to Report First Quarter 2023 Financial Results on May 4, 2023 (GlobeNewswire)
06:39AM	Further Upside For NeuroPace, Inc. (NASDAQ:NPCE) Shares Could Introduce Price Risks After 39% Bounce (Simply Wall St.)
Apr-03-23 04:05PM	NeuroPace to Present at the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -5.15%
Mar-30-23 07:32AM	NeuroPace (NASDAQ:NPCE) adds US$17m to market cap in the past 7 days, though investors from a year ago are still down 44% (Simply Wall St.) +6.96%
Mar-06-23 05:52AM	NeuroPace, Inc. (NASDAQ:NPCE) Q4 2022 Earnings Call Transcript (Insider Monkey) +12.20%
Mar-03-23 06:07AM	Q4 2022 Neuropace Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-02-23 04:05PM	NeuroPace Reports Fourth Quarter & Full Year 2022 Financial Results (GlobeNewswire) -11.21%
Feb-10-23 08:00AM	NeuroPace to Report Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023 (GlobeNewswire)
Jan-09-23 04:03PM	NeuroPace Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Revenue and Appoints Dr. Uri Geiger to Board of Directors (GlobeNewswire) +35.58%
Dec-21-22 04:03PM	NeuroPace to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-30-22 08:00AM	NeuroPace Feasibility Study of Its RNS System for Lennox-Gastaut Syndrome Now Underway (Business Wire)
Nov-11-22 05:25AM	NeuroPace Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-08-22 04:03PM	NeuroPace Reports Third Quarter 2022 Financial Results and Provides a Business Update (GlobeNewswire) +8.58% -16.99%
Nov-04-22 04:03PM	NeuroPace to Present at the 4th Annual Wolfe Research Healthcare Conference (GlobeNewswire)
Oct-25-22 04:03PM	NeuroPace to Report Third Quarter 2022 Financial Results on November 8, 2022 (GlobeNewswire) -9.68%
Oct-21-22 06:44AM	Shareholders in NeuroPace (NASDAQ:NPCE) are in the red if they invested a year ago (Simply Wall St.) -7.36%
Oct-11-22 08:00AM	NeuroPace Announces First Patient Implanted in NAUTILUS Pivotal Study for the Treatment of Idiopathic Generalized Epilepsy (IGE) (Business Wire)
Aug-23-22 04:06PM	NeuroPace to Present at the Morgan Stanley 20th Annual Global Healthcare Conference (GlobeNewswire)
Aug-12-22 02:31AM	NeuroPace, Inc. (NPCE) Q2 2022 Earnings Call Transcript (Motley Fool) -6.96%
Aug-11-22 04:02PM	NeuroPace Reports Second Quarter 2022 Financial Results and Provides a Business Update (GlobeNewswire)
04:02PM	NeuroPace Announces Distribution Agreement with DIXI Medical USA, Provider of Intracranial Electrodes and Instruments for Neurosurgery (GlobeNewswire)
Jul-21-22 04:03PM	NeuroPace to Report Second Quarter 2022 Financial Results on August 11, 2022 (GlobeNewswire)
May-13-22 03:38PM	Shareholders in NeuroPace (NASDAQ:NPCE) are in the red if they invested a year ago (Simply Wall St.)
08:00AM	NeuroPace to Present at the 2022 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
04:30AM	NeuroPace, Inc. (NPCE) Q1 2022 Earnings Call Transcript (Motley Fool)
May-12-22 04:03PM	NeuroPace Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-04-22 08:00AM	NeuroPace Announces First Patient Treated in Pivotal Study Evaluating the RNS System in Adolescents (Business Wire)
Apr-21-22 04:03PM	NeuroPace to Report First Quarter 2022 Financial Results on May 12, 2022 (GlobeNewswire)
Mar-21-22 07:49AM	Meridian Bioscience and NeuroPace have been highlighted as Zacks Bull and Bear of the Day (Zacks)

NeuroPace, Inc. develops, manufactures, and markets implantable devices for treating epilepsy and neurological disorders. It offers implantable components, which include the RNS neurostimulator as well as depth and cortical strip leads. The firm's RNS System is designed for the treatment of medically refractory partial epilepsy and includes implantable and external products. The company was founded by Rebecca L. Kuhn, Frank M. Fischer on November 19, 1997 and is headquartered in Mountain View, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KCK LTD.	10% Owner	Oct 25 '24	Sale	5.45	223,991	1,221,042	5,270,845	Oct 28 03:49 PM
KCK LTD.	10% Owner	Oct 23 '24	Sale	6.02	147	885	5,494,836	Oct 28 03:49 PM
KCK LTD.	10% Owner	Oct 25 '24	Proposed Sale	5.45	223,991	1,221,042		Oct 28 07:02 AM
KCK LTD.	10% Owner	Oct 22 '24	Sale	6.09	4,082	24,853	5,494,983	Oct 24 02:23 PM
KCK LTD.	10% Owner	Oct 18 '24	Sale	6.29	4,878	30,692	5,502,785	Oct 22 10:35 AM
KCK LTD.	10% Owner	Oct 21 '24	Sale	6.10	3,720	22,679	5,499,065	Oct 22 10:35 AM
KCK LTD.	10% Owner	Oct 16 '24	Sale	6.57	6,900	45,336	5,510,957	Oct 18 10:17 AM
KCK LTD.	10% Owner	Oct 04 '24	Sale	6.92	5,757	39,830	5,545,014	Oct 18 10:17 AM
KCK LTD.	10% Owner	Oct 08 '24	Sale	6.43	6,000	38,552	5,534,104	Oct 18 10:17 AM
KCK LTD.	10% Owner	Oct 07 '24	Sale	6.66	4,910	32,687	5,540,104	Oct 18 10:17 AM
KCK LTD.	10% Owner	Oct 14 '24	Sale	6.54	4,031	26,360	5,521,874	Oct 18 10:17 AM
KCK LTD.	10% Owner	Oct 15 '24	Sale	6.50	4,017	26,098	5,517,857	Oct 18 10:17 AM
KCK LTD.	10% Owner	Oct 03 '24	Sale	6.97	3,318	23,115	5,550,771	Oct 18 10:17 AM
KCK LTD.	10% Owner	Oct 17 '24	Sale	6.28	3,294	20,686	5,507,663	Oct 18 10:17 AM
KCK LTD.	10% Owner	Oct 09 '24	Sale	6.10	3,123	19,065	5,530,981	Oct 18 10:17 AM
KCK LTD.	10% Owner	Oct 11 '24	Sale	6.35	2,572	16,320	5,525,905	Oct 18 10:17 AM
KCK LTD.	10% Owner	Oct 10 '24	Sale	6.12	2,504	15,317	5,528,477	Oct 18 10:17 AM
KCK LTD.	10% Owner	Sep 25 '24	Sale	6.60	5,858	38,663	5,578,443	Oct 03 04:15 PM
KCK LTD.	10% Owner	Sep 26 '24	Sale	6.62	5,821	38,535	5,572,622	Oct 03 04:15 PM
KCK LTD.	10% Owner	Sep 27 '24	Sale	6.63	5,059	33,541	5,567,563	Oct 03 04:15 PM
KCK LTD.	10% Owner	Aug 30 '24	Sale	7.76	4,314	33,477	5,589,459	Oct 03 04:15 PM
KCK LTD.	10% Owner	Oct 01 '24	Sale	6.77	4,882	33,051	5,557,932	Oct 03 04:15 PM
KCK LTD.	10% Owner	Sep 30 '24	Sale	6.73	4,749	31,961	5,562,814	Oct 03 04:15 PM
KCK LTD.	10% Owner	Oct 02 '24	Sale	6.87	3,843	26,401	5,554,089	Oct 03 04:15 PM
KCK LTD.	10% Owner	Sep 03 '24	Sale	7.60	2,093	15,907	5,587,366	Oct 03 04:15 PM
KCK LTD.	10% Owner	Sep 13 '24	Sale	7.59	1,993	15,127	5,585,348	Oct 03 04:15 PM
KCK LTD.	10% Owner	Sep 20 '24	Sale	7.50	765	5,738	5,584,583	Oct 03 04:15 PM
KCK LTD.	10% Owner	Sep 23 '24	Sale	7.54	282	2,126	5,584,301	Oct 03 04:15 PM
KCK LTD.	10% Owner	Sep 04 '24	Sale	7.50	14	105	5,587,352	Oct 03 04:15 PM
KCK LTD.	10% Owner	Sep 06 '24	Sale	7.50	11	82	5,587,341	Oct 03 04:15 PM
KCK LTD.	10% Owner	Aug 30 '24	Proposed Sale	7.76	190,000	1,474,400		Oct 03 04:05 PM
ORBIMED ADVISORS LLC	10% Owner	May 01 '24	Sale	14.02	15,690	219,974	3,419,851	May 03 05:16 PM
ORBIMED ADVISORS LLC	10% Owner	May 02 '24	Sale	14.01	8,842	123,876	3,411,009	May 03 05:16 PM
ORBIMED ADVISORS LLC	10% Owner	May 03 '24	Sale	14.03	4,674	65,576	3,406,335	May 03 05:16 PM
ORBIMED ADVISORS LLC	10% Owner	Apr 24 '24	Sale	14.06	1,781	25,041	3,435,541	Apr 26 05:01 PM
ORBIMED ADVISORS LLC	10% Owner	Apr 22 '24	Sale	14.05	24,609	345,756	3,459,113	Apr 23 06:38 PM
ORBIMED ADVISORS LLC	10% Owner	Apr 23 '24	Sale	14.29	21,791	311,393	3,437,322	Apr 23 06:38 PM
ORBIMED ADVISORS LLC	10% Owner	Apr 19 '24	Sale	14.02	18,253	255,907	3,483,722	Apr 23 06:38 PM
ORBIMED ADVISORS LLC	10% Owner	Apr 16 '24	Sale	14.01	14,069	197,107	3,504,898	Apr 18 05:10 PM
ORBIMED ADVISORS LLC	10% Owner	Apr 18 '24	Sale	14.06	2,623	36,879	3,501,975	Apr 18 05:10 PM
ORBIMED ADVISORS LLC	10% Owner	Apr 17 '24	Sale	14.15	300	4,245	3,504,598	Apr 18 05:10 PM
ORBIMED ADVISORS LLC	10% Owner	Apr 11 '24	Sale	14.49	461,899	6,692,917	3,542,068	Apr 15 05:25 PM
ORBIMED ADVISORS LLC	10% Owner	Apr 12 '24	Sale	14.42	23,101	333,116	3,518,967	Apr 15 05:25 PM
Morrell Martha	Chief Medical Officer	Feb 02 '24	Sale	15.07	14,143	213,122	81,208	Feb 06 07:16 PM
Morrell Martha	Chief Medical Officer	Feb 05 '24	Sale	15.17	3,446	52,278	77,762	Feb 06 07:16 PM
Morrell Martha	Chief Medical Officer	Jan 30 '24	Sale	15.10	11,262	170,004	97,937	Feb 01 09:47 PM
Morrell Martha	Chief Medical Officer	Jan 31 '24	Sale	15.08	1,923	28,990	96,014	Feb 01 09:47 PM
Morrell Martha	Chief Medical Officer	Feb 01 '24	Sale	15.04	663	9,971	95,351	Feb 01 09:47 PM
Morrell Martha	Chief Medical Officer	Jan 24 '24	Sale	15.03	827	12,426	109,200	Jan 26 06:04 PM
Morrell Martha	Chief Medical Officer	Jan 25 '24	Sale	15.00	1	15	109,199	Jan 26 06:04 PM
Morrell Martha	Chief Medical Officer	Dec 27 '23	Sale	10.12	13,300	134,648	110,027	Dec 28 05:47 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NPCE

NeuroPace Inc

Upgrade your FINVIZ experience